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Transposition of great vesselsPatients with a systemic right ventricle (SRV) are at high risk for development of heart failure early in life. An SRV
is encountered in patients with congenitally corrected transposition of the great arteries (CCTGA) or dextro-
transposition of the great arteries (DTGA) with previous atrial switch repair (Mustard or Senning procedure).
Progressive heart failure is one of the leading cause of mortality in these patients. Therefore, cardiac
resynchronization therapy (CRT) has gained increasing momentum for use in this challenging congenital heart
disease (CHD) population. However, current guidelines differ in recommendations for CRT in patients with an
SRV as evidence supporting CRT has thus far only been described in case reports and retrospectively in relatively
small study populations. In fact, the European Society of Cardiology Guideline for the management of grown-up
congenital heart disease consider CRT to be ‘experimental’ in this population. This systematic review critically
summarizes current literature on CRT in SRV patients and provides future perspectives for further research in
this challenging and growing CHD population.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac resynchronization therapy (CRT) is an established therapy
for patients with acquired heart disease who develop heart failure
with inter- and intraventricular dyssynchrony. European and North-
American guidelines provide specific indications for CRT in this popula-
tion, however these criteria are not directly applicable to patients with
congenital heart disease (CHD) [1,2]. Advances in medical therapy
have resulted in an ever-increasing population of grown-ups with con-
genital heart disease (GUCH) in whom sudden cardiac death and pro-
gressive heart failure are predominant causes of mortality [3–6]. This
especially true for patients with CHD and a systemic right ventricle
(SRV).
SRV is commonly encountered in the form of congenitally
corrected transposition of the great arteries (CCTGA) or dextro-trophysiology, Department of
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Journal of Cardiology, https:/transposition of the great arteries (DTGA) with previous atrial
switch repair (Mustard or Senning operation) [7–10]. Symptomatic
heart failure frequently occurs in these patients. By the age of 45,
up to 65% of the patients with an SRV are afflicted with symptom-
atic heart failure [10,11]. Nevertheless, the pathophysiological mech-
anisms, and more importantly the interactions between these
mechanisms underlying SRV failure are still incompletely under-
stood. CRT has gained increasing momentum for use in SRV pa-
tients. However, current guidelines differ in recommendations for
CRT in patients with an SRV as evidence supporting CRT has thus
far only been described in case reports and retrospectively in rela-
tively small study populations [12]. In fact, the European Society
of Cardiology Guideline for the management of grown-up congenital
heart disease considers CRT to be ‘experimental’ in the SRV popula-
tion [13]. On the other hand, the more recent Pediatric and Congen-
ital Electrophysiology Society and the Heart Rhythm Society (PACES/
HRS) international guidelines suggest that CRT may be useful in SRV
patients with reduced ejection fraction (≤35%), New York Heart As-
sociation (NYHA) function class ≥ II and QRS duration N150 ms with
a complete right bundle branch block morphology (spontaneous or
paced) [14].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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on CRT in SRV patients and provides future perspectives for further re-
search in this challenging and growing CHD population.
2. Methods
This systematic reviewwas conducted according to Cochrane collab-
oration handbook and Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [15].
2.1. Search strategy
Embase.com (from 1974 to present), Medline ALL via Ovid (from
1946 to present), Cochrane Central Register of Trials (from1992 to pres-
ent) and Web of Science Core Collection (from 1900 to present) were
searched from inception until 7 May 2020 (date last searched), by a
medical information specialist (W.M. Bramer). The search combined
keywords for cardiac resynchronization therapy or biventricular pacing
with terms for congenital heart disease (Supplementary Material).
2.2. Selection criteria
Studies reporting on the outcome of CRT in patients with an SRV
were included. Studies were excluded if the underlying heart disease
was not reported. Studies investigating the outcome of biventricular
pacing in the acute post-operative setting, case (series) reports (defined
as ≤3 patients), abstracts, editorials, reviews and studies written in lan-
guages other than English were excluded from analysis. Patients with
univentricular hearts were also excluded. Finally, we excluded all stud-
ies for which the full text could not be retrieved. Extracted clinical var-
iables from all included studies are summarized in Table 1.
2.3. Data extraction and appraisal
Two researchers (R.K. Kharbanda & J.P. Moore) independently
reviewed the titles and abstracts of all retrieved articles. All identified
potentially relevant articles were screened for adherence to the inclu-
sion and exclusion criteria after which the data was collected in
Microsoft Access 2010. When duplicate reports were suspected, the
most recent publication was included. Data appraisal was not per-
formed, as literature on outcomes of CRT in patients with an SRV is
scarce.
3. Results
The search resulted in 949 articles; after screening titles and ab-
stract, 46 articles were considered for full-text screening. As demon-
strated in Fig. 1, this resulted in 14 studies reporting the outcomes of
CRT in SRV patients. All studies were retrospective in nature and the
key findings are summarized in Table 1.
3.1. Single center studies
The first study to report outcomes of CRT in CHD patients included
solely patients with an SRV [16]. The acute- and mid-term effects of
CRT were evaluated for 8 patients (median age 13 years [7–29]).
Three patients received a purely epicardial CRT-system, 4 patients re-
ceived a mixed-CRT system and purely transvenous lead system was
implanted in only 1 patient. After a median follow-up duration of
17.4 months [7.7–19.7], significant decrease in QRS duration and im-
provement in SRV function assessed by radionuclide ventriculography
was observed. Tricuspid valve regurgitation, however, was not signifi-
cantly reduced by CRT (mean grade prior 2.1 ± 1 vs. mean grade post
1.6 ± 1.4). This proof of concept study showed that CRT could be prom-
ising in “preventing” progressive SRV failure. The study was mainlyPlease cite this article as: R.K. Kharbanda, J.P. Moore, Y.J.H.J. Taverne, et
ventricle: A systematic review, International Journal of Cardiology, https:/limited by a low number of patients with none affected by severe
heart failure.
Subsequently, several smaller studies demonstrated conflicting re-
sults on efficacy of CRT in SRV patients (Table 1). One such study was
performed by Cecchin et al. who examined both echocardiographic
and clinical response in 60 CHDpatients receiving CRT [17]. The authors
identified SRV non-responders as b10% increase in RV ejection fraction
as compared to baseline. Subgroup analyses of 9 SRV patients
(27 years [0.5–43]) with a median follow-up period of only 8 months,
showed acute improvement in 5 patients (55.6%). Despite a favorable
acute response in the majority of the patients, a responder rate of only
25%was reported over long-term follow-up. Another study from Jauvert
et al. reviewed 7 SRV patients (24.6 years [15–50]) in order to assess
echocardiographic and clinical effects of CRT in the presence of TGA
[18]. All patients were in NYHA functional class III with a failing SRV
and interventricular dyssynchrony of whom 5 patients received a
mixed CRT-system. After a mean follow-up time of 19.4 ± 8.1 months,
mean NYHA class decreased from 3 to 1.6, Vo2 max increased from
13.8 ± 2.5 ml/kg/min to 22.8 ± 6.7 ml/kg/min and QRS duration de-
creased from160±31ms to 120±28ms. Importantly, several patients
had single chamber ventricular pacing for sinus node dysfunction at
baseline.
Yeo et al. reported on 7 CCTGA patients undergoing CRT (46 ±
10 years) and included two comparison groups of chronic
subpulmonary LV pacing and un-paced patients [19]. There was no
clear definition used to determine CRT response and data were not re-
ported for each patient separately. The CRT group experienced signifi-
cant improvement in NYHA class (p = .03) and SRV fractional area of
change (FAC) (pre 22% vs CRT 30.7%, p= .03). Multivariate subanalyses
demonstrated that chronic subpulmonary LV pacing was associated
with SRV dysfunction (HR = 2.7 (10–7.0)) and SRV dilatation (HR =
4.7 (1.1–20.6)) which eventually resulted in deterioration of functional
status. These undesirable effects were not observed in the CRT group,
raising the question of whether CRT should be considered in SRV pa-
tients requiring ventricular pacing, even in the absence of baseline RV
dysfunction.
Another single center study included 4 TGA patients (age 31.5 years
[9–47]) with a median follow-up of 4 years after implantation of a CRT
device (epicardial CRT-system: n = 3, transvenous CRT-system: n =
1).[20] Another novel definition of CRT response was introduced. Re-
sponders were defined as those with N7% increase in systemic blood
pressure between CRT on versus off during the perioperative period,
N5% decrease in cardiothoracic ratio or improvement in NYHA class. De-
spite a decrease in QRS duration, none of the patients met any of these
criteria and thus all 4 patients were classified as non-responders.
More recently, the same authors expanded their cohort and introduced
another novel definition to identify responders [21]. In the presence of
ventriculography during follow-up, responders were classified as hav-
ing a b15% decrease in SRV end-systolic volume index. In the remaining
patients in whom ventriculography was unavailable, responders were
defined as patients with a N5% decrease in cardiothoracic ratio or im-
provement in NYHA class. Of the 27 included CHD patients, 8 had an
SRV (baseline characteristics not further specified). Four patients were
labeled as responders, of whom 1 did not have symptoms of heart fail-
ure at baseline and 2 patients had no SRV conduction delay. Non-
optimal lead position (not further specified) in 2 patients was consid-
ered as another explanation for no response. Shortening of QRS dura-
tion, indicating improved electrical synchronization, did not result in
clinical improvement. The severity of systemic atrioventricular valve
function was not reported.
More recently, Karpawich et al. used an invasivemeasure of contrac-
tility (dP/dt-max) with a catheter within the SRV as a pre-implant
screening tool in CHD patients[45]. Six DTGA and 2 CCTGA adult pa-
tients (age 25 [24–39]) showed an initial dP/dt-max improvement of
≥15% and received CRT. During amedian follow-up timeof 2.7 years, he-
modynamic benefits of CRT persisted in all patients. Hence, this studyal., Cardiac resynchronization therapy for the failing systemic right
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Fig. 1. PRISMA flowchart demonstrating selection of papers reporting on outcomes of
cardiac resynchronization therapy in patients with a systemic right ventricle.
4 R.K. Kharbanda et al. / International Journal of Cardiology xxx (2020) xxxdemonstrated that invasive dP/dt-max measurement could be a prom-
ising diagnostic tool for patient selection.
The largest single center study to date on CRT in CCTGA focused not
only on clinical outcome, but also on technical challenges associated
with CCTGA anatomy during transvenous CRT implantation [22]. Re-
sponders were defined as patients with baseline NYHA class ≥2 demon-
strating sustained improvement in NYHA class by at least 1 grade or an
increase in SRV FAC of ≥10% within 3 months after CRT. Of 20 patients
(age 40± 15 years), 12 patients had symptomatic congestive heart fail-
ure. Of the patients with congestive heart failure, acute improvement
was observed in 67% (n= 8), but 25% (n= 2) showed loss of response
during a median follow-up period of 4.6 years. Of the 8 asymptomatic
patients, only 1 experienced progressive heart failure and underwent
heart transplantation after 12 years. After 7.7 years of follow-up, the re-
maining 7 patients hadminimal symptoms. These findings, substantiate
the results reported by Janousek et al. [16], indicating that CRT may be
effective in “preventing” progression of SRV failure. Despite anatomical
challenges, transvenous lead placement attempts were successful in all
but one CCTGA patient. Leads were positioned within either basal or
mid-RV body (n = 12, 60%) or RVOT (n = 8, 40%). Patients with an
RVOT lead appeared to have lower CRT response (HR = 7.1, p= .026).
Finally, a new technique for hybrid transcatheter-surgical lead im-
plantation was introduced. Six patients underwent detailed endo- and
epicardial electro-anatomical SRV mapping followed by epicardial lead
placement. CRT response was defined as improvement in SRV function
with ≥10% in FAC or an improvement in NYHA class by at least 1
grade. All patients showed improvement in NYHA class and significant
reduction in median QRS duration (193 to 147 ms, p b .001). All but
one patient showed improvement in FAC; of whom 5 patients demon-
strated even an improvement of ≥10%. After a median follow-up time
of 11 months (IQR 5–14months), 2 out of 3 patients whowere initiallyPlease cite this article as: R.K. Kharbanda, J.P. Moore, Y.J.H.J. Taverne, et
ventricle: A systematic review, International Journal of Cardiology, https:/referred for heart transplant no longer fulfilled the criteria for transplan-
tation. Larger, long-term follow-up studies are essential to determine
the future role of hybrid CRT implantation in this population.
3.2. Multicenter studies
Themulticenter studies investigating CRT efficacy in SRV patients re-
port promising outcomes with low non-responder rates [23–25]. Dubin
et al. reported a multi-center experience of both CHD and acquired
heart disease pediatric and adult patients that included 17 SRV patients
(12.7 years [4.9–50]). Seventy-one percent (12/17) were identified as
responders (defined as showing any increase in RV ejection fraction)
[23]. Thirteen patients also showed improvement in NYHA class. The
number of adult patients included was not specified, nor was the out-
come specified for patients with transvenous systems versus epicar-
dial/mixed systems. Adverse events among transvenous versus
epicardial/mixed systems were similar at early (22% vs. 17%, respec-
tively) and late (15% vs. 5%) time points among the total cohort of 103
CHD patients.
Anothermixed retrospectivemulticenter study of CHD and acquired
heart disease included 27 SRV patients with a median follow-up of
7.3months and reported a non-response rate of only 13.6% [24]. SRV pa-
tients showed a less favorable outcome of CRT and a higher degree of
systemic atrioventricular valve regurgitation compared to patients
with a systemic LV (SLV). The difference in response could be explained
by variation in underlyingmechanismof systemic atrioventricular valve
regurgitation, SRV anatomy and physiology, prior cardiopulmonary by-
pass, and higher burden of atrial arrhythmia. Hence, surgical correction
of severe systemic atrioventricular valve regurgitation in combination
with CRT was highlighted as a potential efficient treatment strategy in
SRV patients.
3.3. Studies reporting exclusively GUCH patients with an SRV
The above-mentioned studies examined mixed populations includ-
ing both pediatric and adult patients. Koyak et al. were the first to pub-
lish outcomes of CRT in an exclusively adult cohort including 10 SRV
patients (median age 40 years) [25]. Patients showing either improve-
ment in NYHA class or in SRV ejection fraction by at least one category,
were classified as CRT responders. Themedian follow-up duration of the
total cohort was 2.6 years and was not specified for the SRV group sep-
arately. Four patients showed clinical improvement and 2 in SRV echo-
cardiographic function, yielding a response rate of 60%. There was no
significant decrease in QRS duration (pre CRT 162 ± 44 ms vs. post
CRT 157 ± 25 ms). Less favorable long-term outcomes were reported
by another single-center study conducted by Yin et al. who also focused
on exclusively adult SRV patients. After long-term follow-up
(4–5 years), 40% of the patients were identified as CRT responders, de-
fined as ≥5% absolute increase in SRV function or FAC [26].
4. Discussion
4.1. Summarizing current experience where guidelines do not apply
The goal of this systematic review is to summarize studies reporting
the available data for CRT in SRV patients, as current guidelines lack
clear recommendations for this patient group. In general, heterogeneity
in sample size, cohort composition and definitions to measure CRT effi-
cacy was striking (Table 1). Uniform nomenclature for definitions for
‘responders’ and ‘non-responders’ is essential when comparing study
outcomes. For example, of the two large multicenter studies to date,
the former defined ‘non-responder’ as either no change or deterioration
in SRV function [23] while the latter defined ‘non-responder’ as either
no change or deterioration in SRV function and no clinical response de-
fined as a decrease in NYHA class [24]. Besides changes in echo- and
electrocardiographic parameters, the latter study also included clinicalal., Cardiac resynchronization therapy for the failing systemic right
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sensus on defining ‘responders’ and ‘non-responders’ is essential to
compare outcomes of CRT in this challenging patient population.
Based onmost of the retrospective collected data included in this re-
view, the European working group on CHD recommends that CRT can
be considered in patients in NYHA class ≥ II, impaired systemic right
ventricular function (ejection fraction ≤35%) and right bundle branch
block QRS morphology (N150 ms, spontaneous or paced) [27]. Impor-
tantly, this excludes CCTGA patients with left-sided RV failure who typ-
ically display a LBBB pattern. So far, most studies have reported
outcomes of CRT therapy in mixed populations with limited follow-up
data. At present, long term outcomes, clinical profiles, influence of
lead location and identification of risk factors predicting therapy failure
remain unknown.
4.2. Systemic right ventricle
The RV clearly differs in embryological origin, anatomy, functional
properties and electrophysiological characteristics as compared to the
LV. The crescent-shaped RV iswrapped around the LV, has a unique lon-
gitudinal activation pattern, lower oxygen requirement and lower coro-
nary blood flow compared to the LV [28]. The RV, normally supporting
the low-pressure pulmonary system, is prone to fail when supporting
the systemic circulation. In contrast to SLV failure, less is known regard-
ing the pathophysiology and outcomes of different therapeutic options
in patients with SRV failure. Moreover, SRV failure is an important pre-
dictor of long-term morbidity and mortality. An SRV is encountered in
patients with DTGA and previous Mustard or Senning operation or
CCTGA. Clinically, these are different entities with differences in anat-
omy, physiology, surgical history and hence scar tissue and the co-
existence of atrial and ventricular tachyarrhythmias which may influ-
ence outcomes of CRT [29–31].
CCTGA is characterized by atrio-ventricular and ventriculo-arterial
discordance and is often associated with additional cardiac anomalies,
such as ventricular septal defect, pulmonary valve stenosis, Ebstein
anomaly and spontaneous atrioventricular conduction disturbances. In
the absence of these additional cardiac anomalies, patients may be
asymptomatic in early life and heart failure usually develops around
the 4th decade of life. D- and CCTGA patients have a risk for multiple
re-operations due to residual defects or valvular dysfunction, pace-
maker implantation and increased scar tissue predisposing these
patients to atrial and ventricular tachyarrhythmias. Systemic atrioven-
tricular valve regurgitation or residual shuntsmay re-inforce SRV failure
by ventricular dilation resulting in progressive functional decline. Par-
ticularly in CCTGA patients with an intrinsically abnormal Ebsteinoid
systemic atrioventricular valve, progressive regurgitation and subse-
quent SRV volume overload and dilatation may ensue [32]. In addition
to the surgical risk, patients with CCTGA have abnormal shift of the
atrioventricular septum, with abnormal position of the conduction
system. This predisposes to the risk of atrioventricular conduction dis-
turbance, often necessitating pacemaker implantation. Yeo et al. dem-
onstrated that chronic univentricular subpulmonary LV pacing in
CCTGA patients predicted long-term deterioration of SRV function and
NYHA class [19]. In a similar study, Horovitz et al. evaluated the long-
term effects of chronic LV pacing in DTGA patients on cardiac function,
ventricular dyssynchrony and functional status [33]. Again, long-term
chronic LV pacing was associated with decreased functional status,
impaired SRV function and enhanced inter- and intraventricular
dyssynchrony. Future randomized studies are needed to determine
the role of CRT in preventing pacing induced ventricular dysfunction
in this vulnerable CHD population.
4.3. Anatomical challenges during SRV lead implantation
Understanding the underlying anatomy of the coronary venous sys-
tem is essential when considering CRT in SRV patients. In CCTGAPlease cite this article as: R.K. Kharbanda, J.P. Moore, Y.J.H.J. Taverne, et
ventricle: A systematic review, International Journal of Cardiology, https:/patients, the coronary sinus, which is the gateway for ventricular lead
implantation, drains predominantly from the SRV. To date, studies ex-
amining individual variations in the anatomy of the coronary sinus
ostia are scarce [34]. Recently, Moore et al. examined the coronary ve-
nous anatomy in 19 CCTGA patients undergoing transvenous SRV lead
implantation [22]. In line with data from the largest post-mortem
study [35], the coronary venous anatomy differed from conventional
(n=7),with separate ostia (n=7), dual ostia (n=3) or venous drain-
age through the vein of Marshall (n = 2). A transvenous approach was
still successful in 18 patients (95%) indicating that despite anatomical
variations, this approach is feasible for most CCTGA patients. Both com-
puted tomographic (CT) andmagnetic resonance imaging (MRI) can be
used for appropriate pre-procedural planning [36]. In addition, correlat-
ing the coronary venous anatomy with segmental wall motion abnor-
malities defined by echocardiography or (non-) invasive ventricular
activation mappingmay provide relevant anatomical and functional in-
formation to determine optimal lead location.
4.4. Optimal lead location
Despite increasing experience, optimal lead location for both percu-
taneous and epicardial lead implantation has not been defined. Empiric
lead placement or lead positioning at the latest site of ventricular activa-
tion are commonly used strategies in clinical practice. Except for one,
none of these studies, performed subanalyses on the various lead loca-
tions and CRT response. In a cohort of 20 patients, the final lead position
waswithin the basal or mid-RV body in 12(60%) patients and RVOT in 8
(40%)[37]. Patients with an RVOT lead appeared to have higher rate of
heart failure development despite successful CRT (HR = 7.1, p = .03).
The RVOT was only targeted in an attempt to achieve maximum
interlead distance or when no other suitable location could be found.
As SRV contraction relies primarily on circumferential rather than longi-
tudinal shortening, the authors pointed out that pacing at the right ven-
tricular outflow tract (RVOT) may be inferior to mid ventricular pacing.
Differences in CRT responses between patients with a transvenous CRT
system and a mixed/epicardial CRT system also remain unknown.
Recently, the same research group reported the hybrid
transcatheter-surgical CRT approach in order to reduce surgical
exposure and morbidity while retaining benefits of precise localization
of the latest epicardial activation site[38]. Optimistic outcomeswere re-
ported on short-term (11 months), but long-term outcomes in a larger
population are required to substantiate their findings. Various other
strategies such as empiric lead placement, temporary RV pacing at
putative sites and localization of areas of mechanical dyssynchrony by
angiography are also used in clinical practice. At present, it remains
unknown whether the different lead placement strategies result in dif-
ferent outcomes.
4.5. Parameters for CRT response
Currently, there are no uniform criteria to identify CRT responders,
nor are there any pre-defined outcomes to measure efficacy of CRT in
SRV patients. Strikingly, most studies focus more on improvement in
‘numbers’ rather than functionality and quality of life.
All studies included echocardiographic parameters to measure CRT
response. Although echocardiography is a well-established diagnostic
tool to assess SLV function, its use to quantify RV function, and especially
SRV function is extremely challenging and therefore often inaccurate.
The complex geometry, altered loading conditions and the anatomical
positioning affect the reliability and reproducibility of echocardio-
graphic SRV assessment. Furthermore, atrial conduits, septal patches
and residual shunts additionally affect the accuracy of echocardio-
graphic SRV assessment. When precise quantitative ventricular data
are required, cardiacmagnetic resonance (CMR) is considered as the di-
agnostic modality of choice [39]. However, in many SRV patients with a
pre-existing pacemaker or internal cardiac defibrillator, use of CMR isal., Cardiac resynchronization therapy for the failing systemic right
/doi.org/10.1016/j.ijcard.2020.06.052
Fig. 2.Overview of the ESC, AHA/ACC and the PACES/HRS Expert Consensus recommendations. AHA/ACC=American College of Cardiology/American Heart Association, ESC= European
Society of Cardiology, PACES/HRS = Pediatric and Congenital Electrophysiology Society (PACES)/Heart Rhythm Society.
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diographic variable to determine CRT efficacy. Based on the studies in-
cluded in this systematic review, not all SRV patients with shortening
of QRS duration showed improvement in mechanical contraction
and functional status. Several other studies performed in patients
with ischemic cardiomyopathy demonstrated that mechanical
resynchronization rather than QRS duration is a better predictor for
CRT response [40,41]. Whether this also accounts for CHD patients and
more specific SRV patients, still remains to be investigated.
Finally, NYHA classification is commonly used to monitor functional
status of patients with heart failure. Studies included in this review,
solely reported NYHA class when assessing the functional status. On
the one hand, NYHA class is easy to use in clinical practice, on the
other hand, elements of patient and doctor subjectivity are inevitable.
Diller et al. were the first to assess the relationship between objective
exercise capacity and NYHA class in 335 GUCH patients [42]. The
study outcomes showed that indices of cardiopulmonary exercising
such as peak Vo2 are superior to patient reported heart failure symp-
toms. This data highlights the important additional value of objective
exercise testing during follow-up of GUCH patients with CRT.
Although CRT has been applied in SRV patients for more than
15 years, there are no uniform criteria or consensus defining responders
and non-responders. Response rates vary in current literature and are
highly dependent on the criteria used (Table 1). Future studies are rec-
ommended to focus on a homogenous group and distinguish between
improvement in functional state (subjective versus objective), electro-
cardiographic changes (QRS duration), echocardiographic changes
(FAC, ventricular dimensions, ejection fraction etc.) but also quality of
life. Surprisingly, to date, there are no studies examining quality of life
or simple results of 6-minwalk test in SRV patients with CRT. Reporting
all these outcomes separately in future studies, will hopefully result in
more accurate criteria to identify CRT responders in this unique and
challenging population.5. Limitations
Lack of clear recommendations in guidelines may have resulted in
variability in center-specific policies. In addition, depending on patient
volumes, the level of expertise may also differ between centers. Also,Please cite this article as: R.K. Kharbanda, J.P. Moore, Y.J.H.J. Taverne, et
ventricle: A systematic review, International Journal of Cardiology, https:/there are no uniform pre-selection criteria nor pre-defined measures
to examine efficacy of CRT therapy. Centers used non-uniform defini-
tions to identify ‘responders’which subsequently impairs reliable com-
parison of study outcomes. Echocardiographic assessment of SRV
dimensions and function is extremely challenging, thereby possibly af-
fecting its validity and reproducibility.
6. Conclusion and future perspectives
This systematic review summarizes outcomes of CRT in patients
with an SRV. Regardless of limitations of the studies included in this re-
view, data indicates that CRT can be an effective treatment for patients
with a failing SRV. Guidelines are cautious with CRT recommendations
as evidence supporting CRT in this population has been limited to rela-
tive small studies in which adults and pediatric patients with different
underlying defects, including chanelopathies and cardiomyopathies,
are included. Importantly, long-term outcomes are also lacking. Due to
the aforementioned reasons, recommendations on CRT in SRV patients
are absent in the ESC and AHA/ACC guidelines [12,13]. PACES/HRS Ex-
pert Consensus Statement on the Recognition and Management of Ar-
rhythmias in Adult CHD has attempted to provide clinical guidance
(Fig. 2) [43]. However, these recommendations aremainly extrapolated
from large cohorts of patients with ischemia induced heart failure. Fu-
ture studies are essential to further elucidate and substantiate the
abovementioned guidelines. Uniform nomenclature is essential in
order to reliably compare outcomes of studies. Hence, when reporting
on outcomes of CRT in patients with CHD, the following features are
recommended:
• Amount: A sufficient number of patients, ideally in the form of a large
multicenter study dedicated to SRV patients and eventually in the
form of a prospective registry, is needed to perform sophisticated
risk analysis.
• Distinction: Distinction between pediatric-adults, short- and long-
term outcomes, systemic left- and systemic right ventricle,
transvenous- and epicardial lead systems, final lead locations and
sex differences are essential for clinical guidance.
• Clarification: Clarify definition of ‘responders’ and distinguish
between outcome in functional class (subjective/objective),
electrophysiological- and electrocardiographic changes. Advances inal., Cardiac resynchronization therapy for the failing systemic right
/doi.org/10.1016/j.ijcard.2020.06.052
7R.K. Kharbanda et al. / International Journal of Cardiology xxx (2020) xxxcardiac imaging have resulted in numerous parameters assessing ven-
tricular functionality, dimensions and interventricular dyssynchrony
which are used alternately in studies evaluating CRT in GUCH thereby
hampering comparison of study outcomes. In summary, when defin-
ing ‘responders’ it is important to differentiate between improvement
in ‘numbers’, symptoms and quality of life.
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